Transcatheter aortic valve implantation against conventional aortic valve replacement surgery in high-risk patients with aortic stenosis; a cost-effectiveness analysis

Table 2 Model parameters for the rate of risks and adverse events attributed to strategies

Rate of adverse events and Probability of transition	Base Case	Source
Transient ischemic attack (TIA) TAVI	0.053	[20]
Transient ischemic attack (TIA) SAVR	0.043	[20]
Stroke (TAVI)	0.153	[20]
Stroke (SAVR)	0.125	[20]
Rehospitalization (TAVI)	0.333	[20]
Rehospitalization (SAVR)	0.252	[20]
Myocardial infarction (TAVI)	0.111	[20]
Myocardial infarction (SAVR)	0.082	[20]
New atrial fibrillation (TAVI)	0.158	[20]
New atrial fibrillation (SAVR)	0.304	[20]
New permanent pacemaker implantation (TAVI)	0.155	[20]
New permanent pacemaker implantation (SAVR)	0.13	[20]
Aortic-valve reintervention (TAVI)	0.032	[20]
Aortic-valve reintervention (SAVR)	0.008	[20]
Transient ischemic attack (TIA) TAVI	0.053	[20]
Transient ischemic attack (TIA) SAVR	0.043	[20]
Probability of being at NYHA I) TAVI (0–12 months)	0.36	[14]
Probability of being at NYHA II) TAVI (0–12 months)	0.28	[14]
Probability of being at NYHA III) TAVI (0–12 months)	0.10	[14]
Probability of being at NYHA IV) TAVI (0–12 months)	0.01	[14]
Probability of death for any causes TAVI (0–12 months)	0.25	[14]
Probability of being at NYHA I) SAVR (0–12 months)	0.34	[14]
Probability of being at NYHA II) SAVR (0–12 months)	0.30	[14]
Probability of being at NYHA III) SAVR (0–12 months)	0.07	[14]
Probability of being at NYHA IV) SAVR (0–12 months)	0.02	[14]
Probability of death for any causes SAVR (0–12 months)	0.27	[14]

ISSN: 2191-1991